Cancer drug trial aims to shrink HIV's hiding spots
Disease control
Not yet recruiting
This early-stage study is testing whether adding a cancer drug called venetoclax to standard HIV medication (ART) when treatment is first started can help kill more infected cells. The goal is to shrink the hidden pool of virus that persists even with regular therapy, which could…
Phase: PHASE1 • Sponsor: Thomas Aagaard Rasmussen • Aim: Disease control
Last updated Apr 02, 2026 05:42 UTC